Karen W L Yee (Karen Yee, Karen Wl Yee)

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 32

Top Topics

Acute Myeloid Leukemia

Newly Diagnosed

Top Venues

Leukemia & lymphoma

Current oncology (Toronto, Ont.)

This page only lists publications with an associated author ORCID identifier.

Publications

Gail J Roboz, Guillermo F Sanz, Elizabeth A Griffiths, Karen W L Yee, Hagop Kantarjian, Christian Récher, Michael T Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Árpád Illés, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L O'Connell, Yong Hao, Harold N Keer, Mohammad Azab, Hartmut Döhner
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood advances 8 (8) (2024)
Marta B Davidson, James A Kennedy, Jose-Mario Capo-Chichi, Yuliang Shi, Wei Xu, Verna Cheung, Andrea Arruda, Aniket Bankar, Guillaume Richard-Carpentier, Steven Chan, Dawn Maze, Mark D Minden, Aaron D Schimmer, Andre C Schuh, Hassan Sibai, Karen W L Yee, Anne Tierens, Auro Viswabandya, Vikas K Gupta
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN. Blood advances 8 (5) (2024)
Maria Agustina Perusini, Claire Andrews, Atenafu G Eshetu, Vikas K Gupta, Dawn Maze, Karen W L Yee, Aniket Bankar, Marta B Davidson, Guillaume Richard Carpentier, Steven M Chan, Aaron David Schimmer, Jad Sibai, Salman Alharbi, Josephine A Lucero, Swe Mar Linn, Mark D Minden, Andre C Schuh, Hassan Sibai
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol. Leukemia 38 (4) (2024)
Gail J Roboz, Guillermo F Sanz, Elizabeth A Griffiths, Karen W L Yee, Hagop Kantarjian, Christian Récher, Michael T Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Árpád Illés, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L O'Connell, Yong Hao, Harold N Keer, Mohammad Azab, Hartmut Döhner
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood advances 8 (8) (2024)
Maria Agustina Perusini, Claire Andrews, Atenafu G Eshetu, Vikas K Gupta, Dawn Maze, Karen W L Yee, Aniket Bankar, Marta B Davidson, Guillaume Richard Carpentier, Steven M Chan, Aaron David Schimmer, Jad Sibai, Salman Alharbi, Josephine A Lucero, Swe Mar Linn, Mark D Minden, Andre C Schuh, Hassan Sibai
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol. Leukemia (2024)
Leslie Verville, Cassandra McKay, Tom Kouroukis, Suzanna Apostolovski, Mitchell Sabloff, Rena Buckstein, Kardi Kennedy, Karen W L Yee, Amanda Eakins, Christopher Bredeson
Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario. Current oncology (Toronto, Ont.) 31 (8) (2024)
Gail J Roboz, Guillermo F Sanz, Elizabeth A Griffiths, Karen W L Yee, Hagop Kantarjian, Christian Récher, Michael T Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Árpád Illés, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L O'Connell, Yong Hao, Harold N Keer, Mohammad Azab, Hartmut Döhner
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood advances 8 (8) (2024)
Marta B Davidson, James A Kennedy, Jose-Mario Capo-Chichi, Yuliang Shi, Wei Xu, Verna Cheung, Andrea Arruda, Aniket Bankar, Guillaume Richard-Carpentier, Steven Chan, Dawn Maze, Mark D Minden, Aaron D Schimmer, Andre C Schuh, Hassan Sibai, Karen W L Yee, Anne Tierens, Auro Viswabandya, Vikas K Gupta
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN. Blood advances 8 (5) (2024)
Leslie Verville, Cassandra McKay, Tom Kouroukis, Suzanna Apostolovski, Mitchell Sabloff, Rena Buckstein, Kardi Kennedy, Karen W L Yee, Amanda Eakins, Christopher Bredeson
Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario. Current oncology (Toronto, Ont.) 31 (8) (2024)
Maria Agustina Perusini, Claire Andrews, Atenafu G Eshetu, Vikas K Gupta, Dawn Maze, Karen W L Yee, Aniket Bankar, Marta B Davidson, Guillaume Richard Carpentier, Steven M Chan, Aaron David Schimmer, Jad Sibai, Salman Alharbi, Josephine A Lucero, Swe Mar Linn, Mark D Minden, Andre C Schuh, Hassan Sibai
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol. Leukemia 38 (4) (2024)
Marta B Davidson, James A Kennedy, Jose-Mario Capo-Chichi, Yuliang Shi, Wei Xu, Verna Cheung, Andrea Arruda, Aniket Bankar, Guillaume Richard-Carpentier, Steven M Chan, Dawn Maze, Mark D Minden, Aaron D Schimmer, Andre C Schuh, Hassan Sibai, Karen W L Yee, Anne Tierens, Auro Viswabandya, Vikas K Gupta
Outcomes of intensive and nonintensive blast-reduction strategies in accelerated and blast-phase MPN. Blood advances (2024)
Gail J Roboz, Guillermo F Sanz, Elizabeth A Griffiths, Karen W L Yee, Hagop Kantarjian, Christian Récher, Michael T Byrne, Elżbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Árpád Illés, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey L O'Connell, Yong Hao, Harold N Keer, Mohammad Azab, Hartmut Döhner
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: a randomized phase 3 ASTRAL-2 trial. Blood advances 8 (8) (2024)
Leslie Verville, Cassandra McKay, Tom Kouroukis, Suzanna Apostolovski, Mitchell Sabloff, Rena Buckstein, Kardi Kennedy, Karen W L Yee, Amanda Eakins, Christopher Bredeson
Developing Organizational Requirements to Standardize Delivery and Improve Quality of Acute Leukemia Care in Ontario. Current oncology (Toronto, Ont.) 31 (8) (2024)
Maria Agustina Perusini, Claire Andrews, Atenafu G Eshetu, Vikas K Gupta, Dawn Maze, Karen W L Yee, Aniket Bankar, Marta B Davidson, Guillaume Richard Carpentier, Steven M Chan, Aaron David Schimmer, Jad Sibai, Salman Alharbi, Josephine A Lucero, Swe Mar Linn, Mark D Minden, Andre C Schuh, Hassan Sibai
Asparaginase completion among adults including older patients with acute lymphoblastic leukemia treated with a modified DFCI protocol. Leukemia 38 (4) (2024)
Gail J Roboz, Guillermo F Sanz, Elizabeth A Griffiths, Karen W L Yee, Hagop M Kantarjian, Christian Récher, Michael T Byrne, Elzbieta Patkowska, Hee-Je Kim, Xavier Thomas, Ine Moors, Wendy Stock, Arpad Illes, Pierre Fenaux, Yasushi Miyazaki, Takahiro Yamauchi, Casey O'Connell, Yong Hao, Harold Neal Keer, Mohammad Azab, Hartmut Döhner
Guadecitabine vs TC in relapsed/refractory AML after intensive chemotherapy: randomized phase 3 ASTRAL-2 trial. Blood advances (2024)
Josephine Anne Lucero, Salman Al-Harbi, Karen W L Yee
Management of Patients with Lower-Risk Myelodysplastic Neoplasms (MDS). Current oncology (Toronto, Ont.) 30 (7) (2023)
Rena Buckstein, Lisa Chodirker, Karen W L Yee, Michelle Geddes, Heather A Leitch, Grace Christou, Versha Banerji, Brian Leber, Dina Khalaf, Eve St-Hilaire, Nicholas Finn, Thomas Nevill, Mary-Margaret Keating, John Storring, Anne Parmentier, Aksharh Thambipillai, Derek Tang, Christopher Westcott, Chris Cameron, Paul Spin
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma 64 (3) (2023)
Pierre Fenaux, Marco Gobbi, Patricia Kropf, Jean-Pierre J Issa, Gail J Roboz, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop M Kantarjian, Jan Novak, Wieslaw Wiktor Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph M Brandwein, Liana Todorova Gercheva-Kyuchukova, Judit Demeter, Elizabeth A Griffiths, Karen W L Yee, Konstanze Döhner, Yong Hao, Harold Neal Keer, Mohammad Azab, Hartmut Döhner
Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study. Blood advances (2023)
Stéphane de Botton, Pierre Fenaux, Karen W L Yee, Christian Recher, Andrew H Wei, Pau Montesinos, David C Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Carolyn S Grove, Brian A Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Montserrat Arnan, William Blum, Daniela Cilloni, Devendra K Hiwase, Joseph G Jurcic, Jürgen Krauter, Xavier G Thomas, Justin M Watts, Jay Yang, Olga Polyanskaya, Julie Brevard, Jennifer Sweeney, Emma Barrett, Jorge E Cortes
Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML. Blood advances (2023)
Tracy Murphy, Jacqueline M Mason, Brian Leber, Mark R Bray, Steven M Chan, Vikas K Gupta, Dina Khalaf, Dawn Maze, Caroline J McNamara, Aaron David Schimmer, Andre C Schuh, Hassan Sibai, Michael Trus, Debbie Valiquette, Kylie Martin, Linh Nguyen, Xuan Li, Tak W Mak, Mark D Minden, Karen W L Yee
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia (2023)
Rena Buckstein, Lisa Chodirker, Karen W L Yee, Michelle Geddes, Heather A Leitch, Grace Christou, Versha Banerji, Brian Leber, Dina Khalaf, Eve St-Hilaire, Nicholas Finn, Thomas Nevill, Mary-Margaret Keating, John Storring, Anne Parmentier, Aksharh Thambipillai, Derek Tang, Christopher Westcott, Chris Cameron, Paul Spin
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma (2023)
Rena Buckstein, Lisa Chodirker, Karen W L Yee, Michelle Geddes, Heather A Leitch, Grace Christou, Versha Banerji, Brian Leber, Dina Khalaf, Eve St-Hilaire, Nicholas Finn, Thomas Nevill, Mary-Margaret Keating, John Storring, Anne Parmentier, Aksharh Thambipillai, Derek Tang, Christopher Westcott, Chris Cameron, Paul Spin
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma 64 (3) (2023)
Tracy Murphy, Jacqueline M Mason, Brian Leber, Mark R Bray, Steven M Chan, Vikas K Gupta, Dina Khalaf, Dawn Maze, Caroline J McNamara, Aaron David Schimmer, Andre C Schuh, Hassan Sibai, Michael Trus, Debbie Valiquette, Kylie Martin, Linh Nguyen, Xuan Li, Tak W Mak, Mark D Minden, Karen W L Yee
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia 38 (3) (2023)
Tracy Murphy, Jacqueline M Mason, Brian Leber, Mark R Bray, Steven M Chan, Vikas K Gupta, Dina Khalaf, Dawn Maze, Caroline J McNamara, Aaron David Schimmer, Andre C Schuh, Hassan Sibai, Michael Trus, Debbie Valiquette, Kylie Martin, Linh Nguyen, Xuan Li, Tak W Mak, Mark D Minden, Karen W L Yee
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia 38 (3) (2023)
Tracy Murphy, Jacqueline M Mason, Brian Leber, Mark R Bray, Steven M Chan, Vikas K Gupta, Dina Khalaf, Dawn Maze, Caroline J McNamara, Aaron David Schimmer, Andre C Schuh, Hassan Sibai, Michael Trus, Debbie Valiquette, Kylie Martin, Linh Nguyen, Xuan Li, Tak W Mak, Mark D Minden, Karen W L Yee
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia 38 (3) (2023)
Tracy Murphy, Jacqueline M Mason, Brian Leber, Mark R Bray, Steven M Chan, Vikas K Gupta, Dina Khalaf, Dawn Maze, Caroline J McNamara, Aaron David Schimmer, Andre C Schuh, Hassan Sibai, Michael Trus, Debbie Valiquette, Kylie Martin, Linh Nguyen, Xuan Li, Tak W Mak, Mark D Minden, Karen W L Yee
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia 38 (3) (2023)
Rena Buckstein, Lisa Chodirker, Karen W L Yee, Michelle Geddes, Heather A Leitch, Grace Christou, Versha Banerji, Brian Leber, Dina Khalaf, Eve St-Hilaire, Nicholas Finn, Thomas Nevill, Mary-Margaret Keating, John Storring, Anne Parmentier, Aksharh Thambipillai, Derek Tang, Christopher Westcott, Chris Cameron, Paul Spin
The burden of red blood cell transfusions in patients with lower-risk myelodysplastic syndromes and ring sideroblasts: an analysis of the prospective MDS-CAN registry. Leukemia & lymphoma (2023)
Tracy Murphy, Jacqueline M Mason, Brian Leber, Mark R Bray, Steven M Chan, Vikas K Gupta, Dina Khalaf, Dawn Maze, Caroline J McNamara, Aaron David Schimmer, Andre C Schuh, Hassan Sibai, Michael Trus, Debbie Valiquette, Kylie Martin, Linh Nguyen, Xuan Li, Tak W Mak, Mark D Minden, Karen W L Yee
Preclinical characterization and clinical trial of CFI-400945, a polo-like kinase 4 inhibitor, in patients with relapsed/refractory acute myeloid leukemia and higher-risk myelodysplastic neoplasms. Leukemia 38 (3) (2023)
Rena Buckstein, Lisa Chodirker, Lee Mozessohn, Karen W L Yee, Michelle Geddes, Nancy Zhu, April Shamy, Heather A Leitch, Grace Christou, Versha Banerji, Leber Brian, Dina Khalaf, Eve St-Hilaire, Nicholas Finn, Thomas Nevill, Mary-Margaret Keating, John Storring, Robert Delage, Anne Parmentier, Aksharh Thambipillai, Mohammed Siddiqui, Christopher Westcott, Chris Cameron, Alexandre Mamedov, Paul Spin, Derek Tang
A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry. Leukemia & lymphoma (2022)
Naval G Daver, Monique Dail, Jacqueline S Garcia, Brian A Jonas, Karen W L Yee, Kevin R Kelly, Norbert Vey, Sarit Assouline, Gail J Roboz, Stefania Paolini, Daniel A Pollyea, Agostino Tafuri, Joseph M Brandwein, Arnaud Pigneux, Bayard L Powell, Pierre Fenaux, Rebecca L Olin, Giuseppe Visani, Giovanni Martinelli, Maika Onishi, Jue Wang, Weize Huang, Cherie Green, Marion G Ott, Wan-Jen Hong, Marina Y Konopleva, Michael Andreeff
Venetoclax and idasanutlin in relapsed/refractory AML: a non-randomized, open-label phase 1b trial. Blood (2022)
Amer M Zeidan, Pierre Fenaux, Marco Gobbi, Jiří Mayer, Gail J Roboz, Jürgen Krauter, Tadeusz Robak, Hagop M Kantarjian, Jan Novák, Wieslaw Wiktor Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph M Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A Griffiths, Karen W L Yee, Jean-Pierre J Issa, Jan Philipp Bewersdorf, Harold Keer, Yong Hao, Mohammad Azab, Hartmut Döhner
Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood 140 (3) (2022)
Kenny Tang, Andre C Schuh, Karen W L Yee
3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye? Current oncology reports 23 (10) (2021)